O9936377 OBBECE

International Application No. CT/EP00/01955

Attorney Docket No.: BM45379

- 29. The isolated polypeptide of claim 25, wherein the polypeptide is according to (b).
- 30. An isolated polynucleotide encoding a polypeptide of Claim 29 or the full complement to the isolated polynucleotide.

14 Citis

- The isolated polypeptide of claim 25, wherein the immunogenic fragment of (b) comprises at least 20 amino acids.
- 32. The isolated polypeptide of Claim 25 wherein the isolated polypeptide of (a) consists of one of SEQ ID NOs:2, 4, 6, 8 and 10.
- 33. An isolated polynucleotide encoding a polypeptide of Claim 32 or the full complement to the isolated polynucleotide.
- A process for expressing the polynucleotide of Claim 33 comprising transforming a host cell with an expression vector comprising the polynucleotide and culturing the host cell under conditions sufficient for expression of the polynucleotide.
- 35. A fusion protein comprising the isolated polypeptide of Claim 25.
- 36. An isolated polynucleotide comprising the polynucleotide of one of SEQ ID NOs:1, 3, 5, 7 and 9.
- An isolated polynucleotide segment comprising a polynucleotide sequence or the full complement of the entire length of the polynucleotide sequence, wherein the polynucleotide sequence hybridizes to the full complement of one of SEQ ID NOs:1, 3, 5, 7 and 9 minus the complement of any stop codon, wherein the hybridization conditions include incubation at 42°C in a solution comprising: 50% formamide, 5x SSC (150mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 micrograms/ml denatured, sheared salmon sperm DNA, followed by washing in 0.1x SSC at 65°C; and, wherein the polynucleotide sequence is identical to one of SEQ ID NOs:1, 3, 5, 7 and 9 minus any terminal stop codon, except that, over the entire length corresponding to one

International Application N PCT/EP00/01955

Attorney Docket No.: BM45379

of SEQ ID NOs:1, 3, 5, 7 and 9 minus any terminal stop codon, n_n nucleotides are substituted, inserted or deleted, wherein n_n satisfies the following expression

$$n_n \leq x_n - (x_n \circ y)$$

wherein $\mathbf{x_n}$ is the total number of nucleotides in SEQ ID NOs:1, 3, 5, 7 and 9 minus any terminal stop codon, \mathbf{y} is at least 0.95, and wherein any non-integer product of $\mathbf{x_n}$ and \mathbf{y} is rounded down to the nearest integer before subtracting the product from $\mathbf{x_n}$; and wherein the polynucleotide sequence detects *Neisseria meningitidis*.

- 38. An expression vector comprising the isolated polynucleotide of Claim 26.
- 39. A host cell transformed with the expression vector of Claim 38.
- 40. A vaccine comprising the polypeptide of Claim 25 and a pharmaceutically acceptable carrier.
- The vaccine of Claim 40, wherein the vaccine comprises at least one other *Neisseria* meningitidis antigen.
- 42. An antibody immunospecific for the polypeptide or immunogenic fragment of Claim 25.
- 43. A method for inducing an immune response in a mammal comprising administration of the polypeptide of Claim 25.
- 44. A method of diagnosing a *Neisseria meningitidis* infection, comprising identifying a polypeptide of Claim 25, or an antibody that is immunospecific for the polypeptide, present within a biological sample from an animal suspected of having such an infection.
- 45. A method for inducing an immune response in a mammal comprising administration of the isolated polynucleotide of Claim 26.

l'A